Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466091 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2C19L3MBTL1CYP2D6 | |
| SCHEMBL10495543 | 0.87 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C19L3MBTL1CYP2D6 | |
| SCHEMBL20576326 | 0.84 | CYP1A2 (0.47) | CYP3A4CYP1A2CYP2C19KDM4EPOLB | |
| SCHEMBL9770766 | 0.84 | CYP1A2 (0.47) | CYP3A4CYP1A2CYP2C19L3MBTL1CYP2D6 | |
| SCHEMBL10610427 | 0.83 | CYP3A4 (0.42) | CYP3A4CYP1A2CYP2C19KDM4EPOLB | |
| SCHEMBL18921108 | 0.83 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2C19KDM4EPOLB | |
| SCHEMBL18921106 | 0.81 | MEN1 (0.52) | CYP3A4CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL25279294 | 0.81 | KDM4E (0.52) | CYP3A4CYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL30466097 | 0.81 | KDM4E (0.52) | CYP3A4CYP1A2CYP2C19L3MBTL1KDM4E | |
| SCHEMBL18921136 | 0.81 | MAPK14 (0.42) | CYP3A4CYP1A2CYP2C19L3MBTL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | REGLAGENE, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4448492-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | Reglagene, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-11-19 | — | — | US | disclosed |
| US-10556860-B2 | hTERT modulators and methods of use | ARIZONA BOARD OF REGENTS (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2018-12-06 | — | — | US | disclosed |
| EP-3383841-A1 | hTERT MODULATORS AND METHODS OF USE | The Arizona Board of Regents On Behalf of the University of Arizona (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095969-A1 | hTERT MODULATORS AND METHODS OF USE | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-08 | — | — | WO | disclosed |
| US-4987135-A | Leukemia, melanoma | ISHIHARA SANGYO KAISHA LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0335408-A2 | Substituted benzene derivatives, processes for their production and antitumour compositions containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1989-10-04 | — | — | EP | disclosed |
| US-4863924-A | N-benzoyl urea compounds, antitumorous compositions containing them | ISHIHARA SANGYO KAISHA LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0226104-A2 | N-Benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CYP3A4 4021/4885CYP1A2 3248/4885CYP2C19 4254/4885 |
| US-10556860-B2 | hTERT modulators and methods of use | TERT, POT1, TERF2 | CYP3A4 3312/4885CYP1A2 3946/4885CYP2C19 3492/4885 |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | CD47, RB1, TP53 | CYP3A4 4626/4885CYP1A2 3989/4885CYP2C19 3901/4885 |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CYP3A4 4235/4885CYP1A2 3575/4885CYP2C19 4231/4885 |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | CD47, RB1, TP53 | CYP3A4 4626/4885CYP1A2 3989/4885CYP2C19 3901/4885 |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, POT1, TERF2 | CYP3A4 3312/4885CYP1A2 3946/4885CYP2C19 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.